All studies
Cardiology · Registry · Sweden
Szummer 2020
Acute coronary syndrome
ITTSuperiorityAcademia2/5 disclosures
Comparisons
4
In the analysis
4
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments
Design and methods
- Estimand
- ITT
- Design hypothesis
- Superiority
- Matching / weighting
- IPTW
- Analysis method
- Cox PH
- Missing data
- Multiple imputation
- Covariates adjusted
- 35
- DAG
- No
- QBA
- No
Data and sample
- Data type
- Registry
- Data sources
- 1
- Geography
- Sweden
- Eligible sample
- 14005
- Treated
- 8421
- Control
- 5670
- Emulations
- 1
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: Industry
- COI institutions
- AstraZeneca, Sanofi-Aventis, BMS, Eli-Lilly, MSD, Boeringer-Ingelheim, Novartis, Bayer, Merck
- Funding
- Declared: Public, professional society, NGO
- Funders
- Stockholm County Council, Swedish Medical Association (Svenska Läkarsällskapet), Swedish Heart Association (Svenska Hjärtförbundet), Swedish Heart and Lung Foundation
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2020_Szummer_AcuteCoronarySyndrome
- DOI
- https://doi.org/10.1161/circulationaha.120.050645
- Affiliations
- Karolinska Institutet, Stanford University School of Medicine, Linköping University, Lund University, Uppsala University, University of Gothenburg, Sahlgrenska University Hospital
- Sector
- Academia
- Target trials (study level)
- PLATO
- Registration
- NCT00391872